Artequick

Artequick (developed by Artepharm Co., Ltd.) is an Artemisinin-based Combination Therapy (ACT) antimalarial containing two active pharmaceutical ingredients: artemisinin and piperaquine phosphate.

• Artemisinin: A naturally derived endoperoxide lactone extracted from Artemisia annua. It acts rapidly in the blood stage by releasing free radicals upon interaction with intra-parasitic iron, leading to quick clearance of parasitemia and fast relief of malaria symptoms.

• Piperaquine: A long-acting lipophilic bisquinoline antimalarial derivative. It accumulates within the food vacuole of the parasite, inhibiting heme detoxification into non-toxic hemozoin. The buildup of toxic free heme destroys parasite membranes, providing long-lasting blood concentration to clear residual parasites and prevent relapse.

Artequick is widely recognized for its shortened administration schedule compared to standard 3-day ACTs, often utilizing a simplified 2-dose regimen (given 24 hours apart) or a compressed 24-hour schedule depending on local national treatment protocols.

Primary Medical Indications

Artequick is indicated for adult and pediatric populations in the treatment of acute parasitic infections:

• Uncomplicated Plasmodium falciparum Malaria: First-line curative treatment for acute, uncomplicated malaria caused by P. falciparum or mixed species infections containing P. falciparum.

• Multi-Drug Resistant Malaria: Effective against P. falciparum strains that exhibit resistance to older antimalarial monotherapies (such as chloroquine or sulfadoxine-pyrimethamine).

• Treatment of Non-falciparum Blood-Stage Parasites: Effective against erythrocytic schizonts of Plasmodium vivax, Plasmodium ovale, and Plasmodium malariae (radical cure for liver hypnozoites in P. vivax and P. ovale requires adjunct therapy with primaquine or tafenoquine).

Key Product Specifications & Dosing Forms

Critical Safety Guidelines & Precautions

• Avoid High-Fat Meals: Unlike lumefantrine-based ACTs (which require high-fat meals), piperaquine absorption is significantly increased by dietary lipids, which can raise plasma levels and increase the risk of cardiac side effects. Take Artequick with water or a low-fat meal.

• QTc Prolongation Warning: Piperaquine has the potential to prolong the QTc interval on an ECG. Avoid co-administration with other QT-prolonging drugs (e.g., macrolides, antiarrhythmics, quinine) or in patients with known congenital long QT syndrome or severe electrolyte imbalances.

• Re-Dosing Protocol for Vomiting: If vomiting occurs within 1 hour of taking a dose, re-administer a full replacement dose immediately. If persistent vomiting prevents oral retention, transition to parenteral antimalarial therapy (e.g., IV or IM artesunate).

• Not for Severe/Complicated Malaria: Contraindicated as monotherapy for severe or complicated malaria (e.g., cerebral malaria, severe malarial anemia, pulmonary edema). Severe cases require immediate intravenous antimalarial intervention.

• Prophylaxis Restriction: Artequick is strictly a therapeutic curative agent and must never be used for malaria prophylaxis.